Goldman Sachs Removes Quest Diagnostics (DGX) from Conviction Sell List
More News related to DGX
- Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference
- Wells Fargo Resumes Coverage on Quest Diagnostics (DGX) with a Market Perform
- H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics
- Quest Diagnostics Announces Final Tender Offer Results
- New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)
More News related to Analyst Comments
- FBR Capital Raises Estimates & PT on Trina Solar (TSL) following 3Q09 results
- Broadpoint.AmTech Reiterates a 'Buy' on Precision Castparts (PCP); Issues Top Ten for Owning Shares
- Citi Recommends Stocks in Qatar, UAE, Egypt; Believes Middle East Will 'Catch Up' to Emerging Markets
- Broadpoint.AmTech Maintains a 'Buy' on First Solar (FSLR); Lowers PT and Estimates
- Research Firm Questions Surge In Origin Agritech (SEED)
Goldman Sachs removes Quest Diagnostics Inc. (NYSE: DGX) from its Conviction Sell list, but maintains its Sell rating and $45 price target.
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally.
Related Categories
Analyst CommentsStocks Mentioned
+0.22Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
